Skip to Main Content

INFORMATION FOR

    Diabetes Mellitus - Type 1, Phase II

    Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus (TN-22)

    What is the purpose of this trial?

    The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.

    • Trial with
      National Institute of Diabetes and Digestive & Kidney Diseases (NIDDK)
    • Ages
      3 years and older
    • Gender
      Both

    Contact Information

    For more information about this study, including how to volunteer, contact Melinda Zgorski

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

    • Last Updated
      09/12/2023
    • Study HIC
      #2000023905